Motion sickness in migraine sufferers

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 15, 2005, Pages 2691-2697

  Marcus, Dawn A ^a   Furman, Joseph M ^a   Balaban, Carey D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Migraine; Motion sickness; Serotonin; Triptan; Vertigo; Vestibular

Indexed keywords

ELETRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; ZOLMITRIPTAN;

BINDING AFFINITY; CHILDHOOD DISEASE; COMORBIDITY; DISEASE PREDISPOSITION; DIZZINESS; DRUG EFFICACY; DRUG RECEPTOR BINDING; EVOKED VISUAL RESPONSE; FAMILY HISTORY; HUMAN; LEISURE; MIGRAINE; MOTION SICKNESS; NAUSEA AND VOMITING; NONHUMAN; NYSTAGMUS; PATHOGENESIS; PHYSICAL DISABILITY; REVIEW; SYMPTOMATOLOGY; TRAFFIC AND TRANSPORT; TRAVEL; TREATMENT OUTCOME; TRIGEMINAL NUCLEUS; VASODILATATION; VERTIGO;

HUMANS; MIGRAINE DISORDERS; MOTION SICKNESS;

EID: 29244462984     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.15.2691     Document Type: Review

References (50)

1. IRWIN JA: The pathology of sea-sickness. Lancet (1881) 2:907-909.
2. MONEY KE: Motion sickness. Physiological Reviews (1970) 50(1):1-39.
3. HETTLINGER LJ, KENNEDY RS, MCCAULEY ME: Motion and human performance. In: Motion and Space Sickness. Crampton GA, CRC Press, Boca Raton, FL, USA (1990):411-440.
4. GRAYBIEL A, WOOD CD, MILLER EF, CRAMER D: Diagnostic criteria for grading the severity of acute motion sickness. Aerospace Medicine (1968) 39(5):453-5.
5. TURNER M, GRIFFIN MJ: Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics (1999) 42(3):444-461.
6. GRUNFELD E, GRESTY MA: Relationship between motion sickness, migraine and menstruation in crew members of a 'round the world' yacht race. Brain Res. Bull. (1998) 47(5):433-436.
7. DOBIE T, MCBRIDE D, DOBIE T JR, MAY J: The effects of age and sex on susceptibility to motion sickness. Aviat. Space Envrion. Med. (2001) 72(1):13-20.
8. YATES BJ, MILLER AD, LUCOT JB: Physiological basis and pharmacology of motion sickness: an update. Brain Res. Bull. (1998) 47(5):395-406.
9. GRAYBIEL A, KNEPTON J: Sopite syndrome: a sometimes sole manifestation of motion sickness. Aviat. Space Environ. Med. (1976) 47(8):873-882.
10. KAYAN A, HOOD JD: Neuro-otological manifestations of migraine. Brain (1984) 107(Pt 4):1123-1142.
11. FLEMING JB, AMOS AJ, DESMOND RA: Migraine aura without headache: prevalence and risk factors in a primary eye care population. Optometry (2000) 71(6):381-389.
12. DRUMMOND PD: Triggers of motion sickness in migraine sufferers. Headache (2005) 45(6):653-656.
13. TURNER M, GRIFFIN MJ, HOLLAND I: Airsickness and aircraft motion during short-haul flights. Aviat. Space Environ. Med. (2000) 71(12):1181-1189.
14. STANNEY KM, HALE KS, NAHMENS I, KENNEDY RS: What to expect from immersive virtual environment exposure: influences of gender, body mass index, and past experience. Hum. Factors (2003) 45(3):504-520.
15. PARK AH, HU S: Gender differences in motion sickness history and susceptibility to optokinetic rotation-induced motion sickness. Aviat. Space Environ. Med. (1999) 70(11):1077-1080.
16. WEICHENTHAL L, SOLIZ T: The incidence and treatment of prehospital motion sickness. Prehosp. Emerg. Care (2003) 7(4):474-476.
17. WRIGHT MS, BOSE CL, STILES AD: The incidence and effects of motion sickness among medical attendants during transport. J. Emerg. Med. (1995) 13(1):15-20.
18. FORSTBERG J, ANDERSSON E, LEDIN T: Influence of different conditions for tilt compensation on symptoms of motion sickness in tilting trains. Brain. Res. Bull. (1998) 47(5):525-535.
19. LERMAN Y, SADOVSKY G, GOLDBERG E, KEDEM R, PERITZ E, PINES A: Motion sickness-like syndrome among tank simulator drivers. Isr. J. Med. Sci. (1992) 28(8-9):610-615.
20. BAYAZIT Y, YILMAZ M, MUMBUC S, KANLIKANA M: Assessment of migraine-related cochleovestibular symptoms. Rev. Laryngol. Otol. Rhinol. (2001) 122(2):85-88.
21. NEUHAUSER H, LEOPOLD M, VON BREVERN M et al.: The interrelations of migraine, vertigo, and migrainous vertigo. Neurology (2001) 56(4):436-441.
22. LEE H, SOHN SI, JUNG DK et al.: Migraine and isolated recurrent vertigo of unknown cause. Neurol. Res. (2002) 24(7):663-665.
23. MARCUS DA, WHITNEY SL, FURMAN JM: Treatment of migrainous vertigo. Expert. Rev. Neurotheropeutics (2003) 3(3):307-316.
24. LANZI G, BALOTTIN U, FAZZI E, ROSANO FB: The periodic syndrome in pediatric migraine sufferers. Cephalalgia (1983) 3(Suppl. 1):91-93.
25. ABU-ARAFEH I, RUSSELL G: Paroxysmal vertigo as a migraine equivalent in children: a population-based study. Cephalalgia (1995) 15(1):22-25.
26. TAKEDA N, MORITA M, HORII A, NISHIIKE S, KITAHARA T, UNO A: Neural mechanisms of motion sickness. J. Med. Invest. (2001) 48(1-2):44-59.
27. JAVID FA, NAYLOR RJ: The effect of serotonin and serotonin receptor antagonists on motion sickness in Suncus murinus. Pharmacol. Biochem. Behav. (2002) 73(4):979-989.
28. BURSTEIN R, COLLINS B, BAJWA Z, JAKUBOWSKI M: Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: clinical and preclinical evidence. Headache (2002) 42(5):390-391.
29. NEUHAUSER H, RADTKE A, VON BREVERN M, LEMPERT T: Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology (2003) 60(5):882-883.
30. DRUMMOND PD: Motion sickness and migraine: optokinetic stimulation increases scalp tenderness, pain sensitivity in the fingers and photophobia. Cephalalgia (2002) 22(2):117-124.
31. DRUMMOND PD, GRANSTON A: Facial pain increases nausea and headache during motion sickness in migraine sufferers. Brain (2004) 127(3):526-534.
32. FURMAN JM, MARCUS DA, BALABAN C: Migrainous vertigo: development of a pathogenetic model and structural diagnostic interview. Curr. Opin. Neurol. (2003) 16(1):5-13.
33. CHINN HI, SMITH PK: Motion sickness. Pharmacol. Rev. (1955) 7(1):33-82.
34. BALABAN CD, YATES BJ: Vestibulo-autonomic interactions: a teleologic perspective. In: Springer Handbook of Auditory Research: The Vestibular System. Highstein SN, Fay RR, Popper AN (Eds), Springer-Verlag, New York, NY, USA (2004):286-342.
35. BALABAN CD: Vestibular autonomic regulation. Curr. Opin. Neurol. (1999) 12(1):29-33.
36. BALABAN CD, THAYER JF: Neurological bases for balance-anxiety links. J. Anxiety Disord. (2001) 15(1-2):53-79.
37. MARANO E, MARCELLI V, DISTASIO E et al.: Trigeminal stimulation elicits a peripheral vestibular imbalance in migraine patients. Headache (2005) 45(4):325-331.
38. MENÉTREY D, BASBAUM AI: Spinal and trigeminal projections to the nucleus of the solitary tract: a possible substrate for somatovisceral and viscero-visceral reflex activation. J. Comp. Neurol. (1987) 255(3):439-450.
39. CRAIG AD: How do you feel? Interoception: the sense of the physiological condition of the body. Nat. Rev. Neurosci. (2002) 3(8):655-666.
40. MARCUS DA, FURMAN JM: Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med. Sci. Monit. (in press).
41. MARCUS DA, KAPELEWSKI C, RUDY TE, JACOB RG, FURMAN JM: Diagnosis of migrainous vertigo: validity of a structured interview. Med. Sci. Monit. (2004) 10(5):CR197-CR201.
42. 1D receptors. Eur. J. Pharmacol. (1999) 368(2-3):259-268.
43. TFELT-HANSEN P, DE VRIES P, SAXENA PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 60(6):1259-1287.
44. PASCUAL J, DEL ARCO C, ROMON T, DEL OLMO E, CASTRO E, PAZOS A: Autoradiographic distribution of [3H]sumatriptan-binding sites in human postmortem brain. Cephalalgia (1996) 16(5):317-322.
45. 1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res. (2004) 998(1):91-99.
46. 1B/D receptors in the cat: implications for migraine therapy. Cephalalgia (2004) 24(2):99-109.
47. JOHNSTON AR, MURNION B, MCQUEEN DS, DUTIA MB: Excitation and inhibition of rat medial vestibular nucleus neurotics by 5-hydroxytryptamine. Exp. Brain Res. (1993) 93(2):293-298.
48. AMANO T, AKBAR M, MATSUBAYASHI H, SASA M: Inhibitory effects of tandospirone, a 5-HT1A agonist, on medial vestibular nucleus neurons responding to lateral roll tilt stimulation in rats. Brain Res. (2001) 910(1-2):195-198.
49. 1A receptor-mediated inhibition of lateral vestibular nucleus neurons projecting to the abducens nucleus. Brain Res. (1994) 644(1):47-51.
50. GOLDING JF: Motion sickness susceptibility questionnaire revised and its relationship to other forms of sickness. Brain Res. Bull. (1998) 47(5):507-516.